High Blood Pressure Clinical Trial
Official title:
The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function
Aliskiren (also called TekturnaTM) is a new drug for high blood pressure. Aliskiren works by blocking the actions of a substance called renin. Renin is a natural substance in the body that raises blood pressure. Renin is believed to contribute to the production of blood clots by increasing the amount of a substance known as Plasminogen Activator Inhibitor or PAI-1. This study will measure how aliskiren changes the amount of PAI-1 in the blood depending on the time of dosing. The purpose of this study is to find out if it is better to take aliskiren in the morning or at night.
Qualifying subjects will be withdrawn from RAAS blockers in a stepwise fashion over one to
two weeks. All other blood pressure medications will be continued. If the subject's blood
pressure rises above SBP > 170 or DBP > 120 at any time during the study, they will be
excluded and the subject will restart their home medication(s).
Week Two - Visit 2 - Post-taper visit: will be issued hydrochlorothiazide (25mg po, qd x 18
weeks, open label). All study medications will be taken daily between 7 and 10 AM. PAI-1
blood sample will be drawn. Pre-menopausal women will schedule this visit for when they have
began their cycle.
Week Four- Visit 3 - If their BP (> 120/60 mmHg), potassium (≤ 5.5 meq/dl) and renal
function permit (Cr ≤ 1.5 mg/dl), they will be randomized to aliskiren (150 mg po, qd x 2
weeks) or placebo. If applicable, a urine pregnancy test will be done for child bearing age
females.
Week Six - Visit 4 - Titration visit: Subjects will return to the GCRC for an interval
history, pill count, blood pressure check, and basic metabolic panel. If their BP, potassium
and renal function permit, the medication will be increased to aliskiren (300 mg po, qd x 4
weeks) or placebo (double dose). If applicable, a urine pregnancy test will be done for
child bearing age females.
Week Eight - Visit 5 - Post-Titration visit: Subjects will return to the GCRC for an
interval history, pill count, blood pressure check and basic metabolic panel. If their BP,
potassium and renal function permit, they will remain on the current dose of aliskiren.
Week 10 - Visit 6 - Study Day 1 - Patients will be admitted to the GCRC as an inpatient.
They will be asked to lie supine for 24 hours with the head of their bed no higher than 10
degrees. They will have an interval history and physical. An IV catheter will be placed.
After an initial void, they will begin a 24 hour urine creatinine, sodium and aldosterone.
They will have a baseline BMP, high sensitivity C-Reactive Protein (hsCRP) and CBC. They
will have blood drawn every 3 hours for PAI-1 antigen levels, plasma renin activity, plasma
ACE activity, plasma aldosterone levels, plasma cortisol and melatonin. White blood cells
will be harvested in PaxGene tubes for future extraction of white blood cell mRNA. They will
be on a eucaloric, low sodium diet. At the end of the study day they will remain on their
home medications, HCTZ (25mg po, qd), however they will stop their current blinded study
medication (aliskiren or placebo). Subjects will have DNA banked from unused blood buffy
coats. If applicable, UA pregnancy test will be performed by CRC nurses on admission.
Washout Period - The reason for the washout period is four-fold. The washout period insures
that drug is completely washed out of the system before initiation of placebo in the arm
that received aliskiren first. This will allow the study to observe a placebo effect on
blood pressure in the "aliskiren first" arm, in the event that there is one. It would also
insure that that sufficient time has passed between SD1 and SD 2 to see the effect of
placebo on hsCRP in the "aliskerin first" arm. From a safety standpoint, it insures that
subjects have more than 8 weeks to recover their blood counts between study days, as a
significant amount of blood is drawn on each study day. Fourth, as there is a menstrual
variation in Pai-1 levels, it insures that pre-menopausal women participating in the study
will be the same phase of their cycle on SD1 and SD2.
Week 12 - Visit 7 - Mid-Washout visit: Subjects will return to the GCRC for an interval
history, pill count, blood pressure check. If their BP permits (<170/120 mmHg) they will
remain off study medication. If they are anemic (Hgb < 11) they will be started on iron
supplementation.
Week 16 - Visit 8 - Post-Washout visit: Subjects will return to the GCRC for an interval
history, pill count, blood pressure check, BMP and CBC, if indicated. If BP and renal
function permit, the patient will receive their crossover medication (placebo x 2 weeks or
aliskiren 150mg po, qd x 2 weeks). If applicable, a urine pregnancy test will be done for
child bearing age females.
Week 18 - Visit 9 - Titration visit 2: Subjects will return to the GCRC for an interval
history, pill count, blood pressure check, and basic metabolic panel, and CBC if indicated.
If their BP, potassium and renal function permit, the medication will be increased to
aliskiren (300 mg po, qd x 4 weeks) or placebo (double dose).
Week 20 - Visit 10 - Post-Titration visit 2: Subjects will return to the GCRC for an
interval history, pill count, blood pressure check and basic metabolic pane, and CBC if
indicated. If their BP, potassium and renal function permit, they will remain on the current
dose of aliskiren. If their Hgb ≥ 11 mg/dl, they will be able to participate in the final
study day.
Week 22 - Visit 11 - Study Day 2: Patients will be admitted to the GCRC as an inpatient.
They will be asked to lie supine for 24 hours with the head of their bed no higher than 10
degrees. They will have an interval history and physical. An IV catheter will be placed.
After an initial void, they will begin a 24 hour urine creatinine, sodium and aldosterone.
They will have a baseline BMP, hsCRP, and CBC. They will have blood drawn every 3 hours for
PAI-1 antigen levels, plasma renin activity, plasma ACE activity, plasma aldosterone levels,
plasma cortisol and melatonin. White blood cells will be harvested in PaxGene tubes for
future extraction of white blood cell mRNA. They will be on a eucaloric, low sodium diet. At
the end of the study day they will remain on their home medications, and resume home
medications that were previously stopped for study purposes. If applicable, UA pregnancy
test will be performed by CRC nurses on admission.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03812614 -
Comparative Effectiveness of Family vs. Individually Focused Diabetes Education and Support
|
N/A | |
Completed |
NCT03650166 -
High BP and Home Monitoring Experience (HoME) Study
|
N/A | |
Recruiting |
NCT02908139 -
Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients
|
N/A | |
Completed |
NCT01622400 -
Efficacy of a Dedicated Therapeutic Education Program in Patients at High Cardiovascular Risk
|
N/A | |
Completed |
NCT00659672 -
Effect of Whey Protein on Blood Pressure
|
N/A | |
Completed |
NCT00473681 -
Intervention Study to Control High Blood Pressure for Korean American
|
N/A | |
Completed |
NCT03542240 -
Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome
|
N/A | |
Active, not recruiting |
NCT05526092 -
OAT-GUT-BRAIN: Effects of Oats and Rice on Comprehensive Health of Metabolically Challenged Individuals
|
N/A | |
Completed |
NCT02218931 -
ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes
|
N/A | |
Recruiting |
NCT03753204 -
Salt-Sensitivity and Immunity Cell Activation
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04064281 -
The Healthy Cantonese Diet on Cardiometabolic Syndrome
|
N/A | |
Completed |
NCT04479384 -
The Immediate Effect of an Osteopathic Manual Treatment on Blood Pressure in Adults With Hypertension - a Pilot Study.
|
N/A | |
Completed |
NCT04082819 -
MediBeat - HeartBeat Observation Trial
|
N/A | |
Completed |
NCT03555344 -
Effect of Mantra on Hypertensive Patients
|
N/A | |
Withdrawn |
NCT03319823 -
Treating Nocturnal Hypertension and Nocturia in African American Men
|
Phase 4 | |
Completed |
NCT00689819 -
Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients
|
N/A | |
Completed |
NCT00417170 -
Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome
|
Phase 2 | |
Completed |
NCT00130156 -
Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension
|
Phase 4 | |
Completed |
NCT05808556 -
Sticker Pad Containing Essential Oil in Volunteer With High Blood Pressure
|
N/A | |
Recruiting |
NCT05321368 -
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
|
N/A |